Merck KGaA bets on RNAi with $1.3B Silence buyout

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 19 Oct, 13:59 UTC

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

businessscience

Sources

• T2Merck KGaA bets on RNAi with $1.3B Silence buyoutBioPharma Dive / Healthcare Dive / MedTech Dive19 Oct, 13:59